The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Challenges associated with double-hit R/R Burkitt lymphoma & novel therapies being explored
In this video, Ariela Noy, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on emerging therapies for patients with relapsed/refractory (R/R) and double-hit Burkitt lymphoma. Dr Noy emphasizes the poor survival rates for these patients, and highlights the potential of CAR T-cell therapy, but notes that its efficacy is limited. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So patients that have double-hit and Burkitt lymphoma in relapse generally do not do well. As I mentioned a little bit earlier, patients really almost rarely survive, at least if they have Burkitt. I would say survival rates are less than 10 percent, so we’re hoping to do better in the frontline setting to avoid that. But both, well, double-hit, we are trying to take those patients to CAR-T...
So patients that have double-hit and Burkitt lymphoma in relapse generally do not do well. As I mentioned a little bit earlier, patients really almost rarely survive, at least if they have Burkitt. I would say survival rates are less than 10 percent, so we’re hoping to do better in the frontline setting to avoid that. But both, well, double-hit, we are trying to take those patients to CAR-T. The results are not spectacular. And so sometimes those patients end up on clinical trials, looking at novel agents. I would say refer earlier than later to try to capitalize on that. It’s a difficult situation. And we see relapses right after the CAR-T as well. And the CAR-T is not very helpful in the Burkitt. There’s a paper in Blood by samples looking across many institutions. And the CAR-T efficacy for relapsed/refractory Burkitt is terrible, like 15 percent.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
